RCM
BIO icon

Raleigh Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Raleigh Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67K Buy
+6
New +$1.73K ﹤0.01% 562
2025
Q1 		– Sell
-6
Closed -$1.97K – 627
2024
Q4 		$1.97K Sell
6
-6
-50% -$2.04K ﹤0.01% 837
2024
Q3 		$4.01K Buy
12
+5
+71% +$1.59K ﹤0.01% 730
2024
Q2 		$1.91K Buy
7
+4
+133% +$1.16K ﹤0.01% 788
2024
Q1 		$1.04K Buy
3
+2
+200% +$658 ﹤0.01% 842
2023
Q4 		$323 Buy
+1
New +$313 ﹤0.01% 1027
2023
Q2 		– Sell
-81
Closed -$38.8K – 846
2023
Q1 		$38.8K Buy
81
+47
+138% +$22K 0.02% 277
2022
Q4 		$14.3K Buy
34
+22
+183% +$8.88K 0.01% 372
2022
Q3 		$5K Buy
+12
New +$5.98K ﹤0.01% 473

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return